Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 64

1.

The colorful spectrum of Tourette syndrome and its medical, surgical and behavioral therapies.

Roth J.

Parkinsonism Relat Disord. 2017 Aug 10. pii: S1353-8020(17)30285-7. doi: 10.1016/j.parkreldis.2017.08.004. [Epub ahead of print]

PMID:
28807495
2.

Current pharmacotherapeutic approaches for the treatment of Tourette syndrome.

Egolf A, Coffey BJ.

Drugs Today (Barc). 2014 Feb;50(2):159-79. doi: 10.1358/dot.2014.50.2.2097801. Review.

PMID:
24619591
3.

Emerging treatment strategies in Tourette syndrome: what's in the pipeline?

Termine C, Selvini C, Rossi G, Balottin U.

Int Rev Neurobiol. 2013;112:445-80. doi: 10.1016/B978-0-12-411546-0.00015-9. Review.

PMID:
24295630
4.

Clinical pharmacology of dopamine-modulating agents in Tourette's syndrome.

Mogwitz S, Buse J, Ehrlich S, Roessner V.

Int Rev Neurobiol. 2013;112:281-349. doi: 10.1016/B978-0-12-411546-0.00010-X. Review.

PMID:
24295625
5.

Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome.

Wijemanne S, Wu LJ, Jankovic J.

Mov Disord. 2014 Jan;29(1):126-30. doi: 10.1002/mds.25692. Epub 2013 Oct 21.

PMID:
24150997
6.

Canadian guidelines for the evidence-based treatment of tic disorders: pharmacotherapy.

Pringsheim T, Doja A, Gorman D, McKinlay D, Day L, Billinghurst L, Carroll A, Dion Y, Luscombe S, Steeves T, Sandor P.

Can J Psychiatry. 2012 Mar;57(3):133-43. Review.

PMID:
22397999
7.

Pimozide for tics in Tourette's syndrome.

Pringsheim T, Marras C.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006996. doi: 10.1002/14651858.CD006996.pub2. Review.

PMID:
19370666
8.

Aripiprazole in the pharmacotherapy of Gilles de la Tourette syndrome in adult patients.

Kawohl W, Schneider F, Vernaleken I, Neuner I.

World J Biol Psychiatry. 2009;10(4 Pt 3):827-31. doi: 10.1080/15622970701762544.

PMID:
18843565
9.

[Antipsychotics in the treatment of Tourette disorder: a review].

Cath DC, Meynen G, de Jonge JL, van Balkom AJ.

Tijdschr Psychiatr. 2008;50(9):593-602. Review. Dutch.

10.

Levetiracetam in the treatment of antipsychotics-resistant Tourette syndrome.

Oulis P, Karapoulios E, Masdrakis VG, Kouzoupis AV, Karakatsanis NA, Papageorgiou C, Papadimitriou GN, Soldatos CR.

World J Biol Psychiatry. 2008;9(1):76-7.

PMID:
17853302
11.

Emerging drugs in Tourette syndrome.

Silay YS, Jankovic J.

Expert Opin Emerg Drugs. 2005 May;10(2):365-80. Review.

PMID:
15934872
12.

Effectiveness and safety of risperidone for children and adolescents with chronic tic or tourette disorders in Korea.

Kim BN, Lee CB, Hwang JW, Shin MS, Cho SC.

J Child Adolesc Psychopharmacol. 2005 Apr;15(2):318-24.

PMID:
15910216
13.
14.

[Chronic tic disorders--chronic mortor or vocal tic disorders and de la Tourette's syndrome].

Kano Y.

Ryoikibetsu Shokogun Shirizu. 2003;(40):65-71. Review. Japanese. No abstract available.

PMID:
14626066
15.

[Tic syndrome].

Czapliński A, Steck AJ, Fuhr P.

Neurol Neurochir Pol. 2002 May-Jun;36(3):493-504. Review. Polish.

PMID:
12185806
16.

Pharmacological options for the treatment of Tourette's disorder.

Jiménez-Jiménez FJ, García-Ruiz PJ.

Drugs. 2001;61(15):2207-20. Review.

PMID:
11772131
17.

Tourette syndrome: clinical characteristics and current management strategies.

Kossoff EH, Singer HS.

Paediatr Drugs. 2001;3(5):355-63. Review.

PMID:
11393328
18.

Gilles de la Tourette syndrome: symptomatic treatment based on evidence.

Robertson MM, Stern JS.

Eur Child Adolesc Psychiatry. 2000;9 Suppl 1:I60-75. Review.

PMID:
11140781
19.

[Drug treatment of obsessive-compulsive disorder. With proper drugs and some patience many patients can be helped].

Mavrogiorgou P, Hegerl U.

MMW Fortschr Med. 1999 Sep 30;141(39):32-4, 37. German.

PMID:
10897982
20.

Tics in Tourette syndrome: new treatment options.

Awaad Y.

J Child Neurol. 1999 May;14(5):316-9.

PMID:
10342599

Supplemental Content

Loading ...
Support Center